Transcatheter arterialization of the deep veins: 1-year outcomes of PROMISE-UK study

Published Date: 30th July 2024

Publication Authors: Lechareas. S

Abstract:

Approximately 20% of the general population over the age of 55 years have peripheral arterial disease (PAD), which is the main cause of leg amputations in the UK National Health Service (NHS) and other healthcare systems1,2. An estimated 20% of those with symptomatic PAD progress to develop chronic limb-threatening ischaemia (CLTI), the most advanced form of PAD3. A subgroup of patients with CLTI not suitable for conventional endovascular or open revascularization owing to lack of an arterial target for bypass or endovascular intervention, or multiple failed open and endovascular revascularization attempts, are referred to as ‘no-option’ patients. These patients represent up to 20% of all those presenting with CLTI4–6, and historically have been offered major amputation of the affected limb which has an associated 1-year mortality rate of over 30%7. A novel endovascular procedure called transcatheter arterialization of the deep veins (TADV), which uses the only CE mark-approved system has been reported as a potential treatment for selected no-option CLTI patients and is currently available in the UK under special arrangements8–15.

The PROMISE-UK study was conducted with the objective of establishing real-world outcomes among patients with CLTI treated with TADV using the commercially available LimFlow® system (Inari Medical, Irvine, CA, USA) across multiple centres in the UK NHS.

Zayed, H; Lechareas, S; Et al. (2024). Transcatheter arterialization of the deep veins: 1-year outcomes of PROMISE-UK study. British Journal of Surgery. 11(7), p.4. [Online]. Available at: 10.1093/bjs/znae188 [Accessed 2 August 2024].

« Back